| NANB hepatitis | Hepatitis caused by two or more infectious agents not detectable by methods that reveal the presence of hepatitis viruses A and B; one cause, now called type C hepatitis has been identified; may follow blood transfusion and is often seen in chronic renal dialysis patients. Synonym: NANB hepatitis. (05 Mar 2000) |
|---|---|
| neonatal hepatitis | Hepatitis in the neonatal period presumed to be due to a variety of causes, chiefly viral; characterised by direct and indirect bilirubinaemia, hepatocellular degeneration, and appearance of multinucleated giant cells; may be difficult to distinguish from biliary atresia, but is more likely to end with recovery, although cirrhosis may develop. Synonym: giant cell hepatitis. (05 Mar 2000) |
| subacute hepatitis | <pathology> This is a form of continuing liver inflammation that results in liver cell death. Causes include viral infection (hepatitis D, hepatitis B, hepatitis C), autoimmune disease, drug ingestion or metabolic causes. Chronic active hepatitis will lead to hepatic failure and death in a small percentage of these patients. (27 Sep 1997) |
| non-A, non-B hepatitis | Hepatitis caused by two or more infectious agents not detectable by methods that reveal the presence of hepatitis viruses A and B; one cause, now called type C hepatitis has been identified; may follow blood transfusion and is often seen in chronic renal dialysis patients. Synonym: NANB hepatitis. (05 Mar 2000) |
| non-A, non-B hepatitis virus | Term used to group any of a number of viruses, other than A or B, which cause hepatitis in humans. (05 Mar 2000) |
| non-A, non-B, non-C hepatitis | Hepatitis caused by viral organisms other than hepatitis viruses A, B or C. (05 Mar 2000) |
| suppurative hepatitis | Hepatitis with abscess formation; often amoebic in origin. (05 Mar 2000) |
| delta hepatitis | Acute or chronic hepatitis caused by the hepatitis delta virus, a defective RNA virus requiring HBV for replication. The acute type occurs in two forms: 1) coinfection, the simultaneous occurrence of hepatitis B virus and hepatitis delta virus infections, which usually is self-limiting; 2) superinfection, the appearance of hepatitis delta virus infection in a hepatitis B virus carrier, which often leads to chronic hepatitis The chronic type appears to be more severe than other types of viral hepatitis. Synonym: delta hepatitis, hepatitis D. (05 Mar 2000) |
| drug-induced hepatitis | <hepatology, pathology> Inflammation and hepatocellular damage of the liver that is caused by a drug. Some medications may cause inflammation of the liver as a drug side effect or drug toxicity. Drugs that are known to cause hepatitis include acetaminophen, isoniazid, halothane, methyldopa, erythromycin and oral contraceptives. (27 Sep 1997) |
| duck hepatitis virus | A DNA virus of the genus Hepadnavirus, in the family Hepadnaviridae, causing virus hepatitis of ducks. (05 Mar 2000) |
| duck viral hepatitis | An acute, highly contagious disease of young ducklings caused by an enterovirus and characterised by lethargy, spasmodic paddling and rapid death. (05 Mar 2000) |
| immunization, hepatitis a | When immediate protection against hepatitis a (infectious hepatitis) is needed, immunoglobulins are used. Protection is effective only if given within 2 weeks of exposure and lasts but 2-4 months. Immunoglobulins can be used to protect household contacts of someone with acute viral hepatitis and travelers to regions with poor sanitation and high hepatitis a rates, when the traveler has to depart sooner than the vaccines can take effect (about 2 weeks). Travelers can receive the immunoglobulin and vaccine simultaneously and be protected immediately and for longer term. When immediate protection is not needed, hepatitis a vaccines are considered for individuals in high-risk settings, including frequent world travelers, sexually active individuals with multiple partners, homosexual men, individuals using illicit drugs, employees of daycare centres, and certain health care workers, and sewage workers. Two hepatitis a vaccines called havrix and vaqta are commercially available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection. (12 Dec 1998) |
| immunization, hepatitis b | Hepatits B (hep B) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are usually given both hbig and vaccine to provide immediate and long term protection. (12 Dec 1998) |
| immunization, infectious hepatitis | See Immunization, hepatitis a. (12 Dec 1998) |
| immunization, serum hepatitis | See Immunization, hepatitis b. (12 Dec 1998) |